Gujarat Terce Laboratories Ltd Stock Price Today (NSE: GUJTERC)

Gujarat Terce Laboratories Ltd

34.500.56 (1.60%)
Market Closed

Fundamental Score

...

Gujarat Terce Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Gujarat Terce Laboratories Ltd share price today is 34.50, down 1.60% on NSE/BSE as of 19 June 2026. Gujarat Terce Laboratories Ltd (GUJTERC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 34.63 (Cr). The 52-week high for GUJTERC share price is 59.78 and the 52-week low is 29.00. The company has a Return on Equity (ROE) of -14.57% and a debt-to-equity ratio of 0.08.

Gujarat Terce Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
41.00
Low
33.06
Volume
3.5K
Change
-9.15%

Gujarat Terce Laboratories Ltd share price chart: -9.15% return over the past month. 52-week high ₹59.78, 52-week low ₹29.00.

Gujarat Terce Laboratories Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
35.8935.8933.2034.501.81K (Cr)
36.0036.0034.6035.062.91K (Cr)
34.5935.2534.5934.763.21K (Cr)
34.6535.5034.6534.762.26K (Cr)
36.0036.0034.3034.684.20K (Cr)
34.6035.7334.6035.197.55K (Cr)
35.0035.0033.0633.525.42K (Cr)
35.9936.0034.7034.711.19K (Cr)
35.0035.7035.0035.00450.00 (Cr)
33.5035.5933.5034.701.69K (Cr)

Gujarat Terce Laboratories Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
36.0036.0033.2034.50-4.17%
39.3439.3433.0634.76-11.64%
33.8042.0030.5137.61+11.27%
38.3641.9029.0030.90-19.45%
47.5047.5037.2038.36-19.24%
45.9950.0040.0046.00+0.02%
46.8949.9542.0143.50-7.23%
46.0049.4041.5045.18-1.78%
46.3559.7842.0045.75-1.29%
40.7548.0037.2045.49+11.63%
51.0055.9939.0040.75-20.10%
53.0057.8047.0050.13-5.42%

Returns & Performance

Poor

Return on Equity (ROE)

-14.57%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

41.41%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

0.72%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Gujarat Terce Laboratories Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

37.03%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-5.41%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-2.78%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

5.98%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.08x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

14.52x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

2.70 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Gujarat Terce Laboratories Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GUJTERC across key market metrics for learning purposes.

Positive Indicators

4 factors identified

Excellent ROCE Performance (41.41%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Conservative Debt Levels (D/E: 0.08)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (14.52x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Below-Average Return on Equity (-14.57%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Margin Pressure Concerns (0.72%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Gujarat Terce Laboratories Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Gujarat Terce Laboratories Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
8.5/100
35
₹34.63
-14.57%
Poor
41.41%
Excellent
0.1
Excellent
5.98%
Good
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Gujarat Terce Laboratories Ltd Quarterly Performance

Latest quarterly metrics for GUJTERC — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-2.78%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-5.41%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

5.98%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Gujarat Terce Laboratories Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GUJTERC — calculated from daily price history

44RSI 14
Neutral — RSI 44

Momentum is balanced — neither overbought nor oversold.

SMA 50
36
▼ Price below SMA 50 — Short-term bearish
SMA 200
42
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
7K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Gujarat Terce Laboratories Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Gujarat Terce Laboratories Ltd (GUJTERC) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Gujarat Terce Laboratories Ltd

About GUJTERC (Gujarat Terce Laboratories Ltd)

Gujarat Terce Laboratories Ltd is a dynamic pharmaceutical company committed to improving global health through the development, production, and distribution of high-quality medici...nes. With a strong emphasis on research and innovation, GUJTERC strives to create effective therapeutic solutions that address a wide range of medical needs. Leveraging state-of-the-art manufacturing facilities and adhering to stringent international quality standards, the company ensures that its products meet the highest benchmarks of safety and efficacy. Driven by a passion for patient well-being, GUJTERC actively invests in cutting-edge technologies and skilled personnel, fostering a culture of continuous improvement and scientific excellence. GUJTERC's diverse product portfolio caters to various therapeutic segments, providing accessible and affordable healthcare options to patients worldwide. From essential antibiotics and respiratory medications to specialized nutraceuticals and gynecological treatments, the company offers a comprehensive range of pharmaceutical solutions. Committed to innovation, GUJTERC also explores the synergy between modern medicine and traditional healing practices, integrating Ayurvedic principles into its product development process. Through strategic partnerships and collaborations, the company expands its reach and impact, delivering life-changing medicines to communities in need. GUJTERC's unwavering commitment to quality, affordability, and innovation positions it as a trusted partner in healthcare. Beyond its commitment to pharmaceutical excellence, Gujarat Terce Laboratories Ltd is deeply rooted in ethical business practices and corporate social responsibility. The company actively supports community development initiatives, focusing on healthcare access, education, and environmental sustainability. Through transparent operations and a dedication to environmental stewardship, GUJTERC seeks to create long-term value for its stakeholders and contribute to a healthier, more sustainable future. By upholding the highest ethical standards and prioritizing the well-being of both patients and communities, GUJTERC strives to be a responsible and respected leader in the global pharmaceutical industry.

Company Details

Symbol:GUJTERC
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Natwarbhai Purshottamdas Prajapati
Founder & Whole-Time Chairman
Mr. Aalap Natubhai Prajapati
CEO, MD & Whole Time Director
Mr. Bhagirath Ramhit Maurya
Chief Financial Officer

GUJTERC Share Price: Frequently Asked Questions

What is the current share price of Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd (GUJTERC) trades at ₹34.50 on NSE and BSE. Market cap ₹34.63 (Cr). Educational data only.

What is the P/E ratio of Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd has a P/E of N/Ax vs industry average 31.77x.

What is the Bull Run score for Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd has a Bull Run score of 8.5/100 based on 25+ financial parameters.

Does Gujarat Terce Laboratories Ltd pay dividends?

Gujarat Terce Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd has ROE of -14.57%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd has debt-to-equity of 0.08.

Is Gujarat Terce Laboratories Ltd a good investment?

Bull Run gives Gujarat Terce Laboratories Ltd a score of 8.5/100. This is not investment advice — consult a SEBI-registered advisor.